Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cholera vaccine (oral, inactivated)
- Development stage
- Phase 4
- Lead developer
- Shanghai United Cell Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
OraVacs is an oral, enteric-coated capsule vaccine developed for the prevention of cholera and infectious diarrhea caused by enterotoxigenic *Escherichia coli* (ETEC). The formulation consists of inactivated whole cells of *Vibrio cholerae* O1 (including both classical and El Tor biotypes) combined with a recombinant cholera toxin B subunit (rBS). Unlike the liquid suspension formulation of the similar vaccine Dukoral, OraVacs is delivered as a capsule, which protects the active components from gastric acid without the need for a bicarbonate buffer solution. The vaccine induces mucosal and systemic immunity by eliciting secretory IgA and systemic IgG antibodies against the cholera toxin and bacterial lipopolysaccharides. Due to the structural similarity between the cholera toxin B subunit and the heat-labile toxin (LT) of ETEC, the vaccine provides cross-protective efficacy against ETEC-induced traveler's diarrhea. It has been evaluated in Phase 4 clinical trials in China for the prevention of non-cholera infectious diarrhea in pediatric populations.
- Brand names
- OraVacs
- Other names
- oral recombinant B subunit/bacterial cholera vaccinerBS/WC vaccinerecombinant cholera B subunit + bacterial whole-cell vaccineWC/rBS vaccine
02
Targets
LTB (Heat-labile enterotoxin B subunit)V. cholerae O1 LPS (Vibrio cholerae O1 lipopolysaccharide)CTBS (Cholera toxin B subunit)
Beyond the preview
Go deeper on cholera vaccine (oral, inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cholera vaccine (oral, inactivated).